Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SOT 102

Next Previous
X
Search
Drug Profile

SOT 102

Alternative Names: SO-N-102; SOT-102

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NBE-Therapeutics; SOTIO
  • Class Anthracyclines; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma
  • Preclinical Solid tumours

Most Recent Events

  • 23 May 2024 SOTIO Biotech re-initiates a phase I/II trial for Adenocarcinoma in USA, Belgium, France, Spain and Czech Republic (NCT05525286)
  • 28 Nov 2023 Sotio Biotech terminates phase I/II CLAUDIO-01 trial as per the sponsors decision in gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinoma in Belgium, the Czech Republic, Spain, USA and France (NCT05525286)
  • 26 Apr 2022 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Spain, Czech Republic, Belgium (IV) (NCT05525286 ; SN201 ; EudraCT2021-005873-25)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top